About
Dr. Rehan Mujeeb Faridi, PhD, HCLD/CC (ABB)
Clinical Molecular Geneticist · High-Complexity Lab Director · Builder of Next-Generation Diagnostics & Health-Tech
I work at the intersection of clinical genomics, immunology, and software – designing and directing high-complexity labs, deploying cutting-edge NGS assays, and building digital infrastructure that scales modern diagnostics across Canada and the Middle East.
Clinical Practice & Leadership
Clinical & Laboratory Leadership
Director of Molecular Diagnostics at OncoHelix Inc. and Associate Director of OncoHelix-coLAB at Burjeel Medical City, leading advanced genomic testing for oncology and rare disease across Canada and the UAE. Former Section Director (Molecular), Hematology Translational Lab and Lab Scientist III, Molecular Pathology at Alberta Precision Laboratories—bringing first-in-province and first-in-country NGS programs into routine care.
Research & Innovation
Research, Immunogenetics & Diagnostic Innovation
Work recognized by ASH, ASHI, FOCIS, AAAAI, and others in NK-cell immunogenetics, transplant outcomes, reproductive immunology, COVID-19 immunity, and cancer genomics. Co-leads Solasta Software, architecting SLIMS, PRISM, and SHELF—extending from LIMS and order/report portals to universal quality and document management for laboratories.
Timeline
Scroll Through the Years
Postdoctoral Research Fellow, University of Calgary — immunogenetics and transplant medicine within clinical lab environments; foundational NK-cell/KIR work for GVHD/relapse/PTLD risk.
Seminal KIR–HLA and NK-cell biology publications; award-winning abstracts; VEGF/eNOS genetics and recurrent miscarriage; fellowships/distinctions from DBT, CSIR-UGC, CIHR/ACHRI, ASH, ASHI, FOCIS, AAAAI.
Clinically validated and implemented Alberta’s first comprehensive myeloid malignancy NGS panel (routine practice).
Launched Mutational Landscape of Albertan AML (>300 cases) mapping co-occurring/mutually exclusive mutations and prognostic patterns.
Lab Scientist III, Molecular Pathology (South) & Section Director (Molecular), Hematology Translational Lab — led assay development/validation pipelines.
Designed and implemented SLIMS (Solasta LIMS) for complex molecular workflows; scaled AML/myeloid NGS into a mature provincial program.
Clinically validated Illumina TST170 for solid tumors; reconfigured molecular labs for pandemic response.
Co-led early COVID-19 NK-cell study linking impaired counts/cytolytic function with severe disease.
Led COVID-19 genome sequencing and Alberta border-testing pilot; built clinical metagenomics workflows for lineage/copathogen detection.
Metagenomic detection of Alpha/Zeta variants from respiratory samples; continued NK-cell/transplant immunogenetics (IL-10, KIR predictors of GVHD).
Implemented Roche Avenio Tumor CGP (FoundationOne-based) — first-in-Canada deployment; expert panelist at Qiagen Oncology Summit.
Rolled out SLIMS Live (PRISM) — interactive Orders & Reports portal connecting clinicians and labs via structured workflows.
Earned HCLD (ABB) certification; formalized leadership over high-complexity molecular labs.
Advanced large-scale AML and CGP datasets toward integrated liquid biopsy/germline/somatic/immunogenetic analytics across Canada and the Middle East.
Achieved Clinical Consultant (ABB) certification; Director, Molecular Diagnostics (OncoHelix) and Associate Director, OncoHelix-coLAB (Burjeel Medical City), bridging Canadian/UAE precision oncology.
Expanded Solasta product roadmap (regulatory, analytics, integrations) for multi-jurisdictional cancer genomics services.
Leading multi-site molecular programs aligned with evolving accreditation and quality frameworks.
Launched SHELF — universal quality and document management for labs/hospitals/health-tech, integrating policies, SOPs, training, and audits.
What I’m Building Next
Scalable precision oncology and software for safer diagnostics.
If you’re interested in collaborating on clinical genomics, immunology, or laboratory software, let’s connect.